Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals, Inc. (ANEB) — VMCI valuation read

Anebulo Pharmaceuticals, Inc. sits at VMCI 38/100, with the Healthcare sector median at 50. That 12-point spread is the first thing to note on ANEB: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on ANEB are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on ANEB: ANEB trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of -0.4x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

ANEB rose 3.3% over the trailing 7 days, with a -2.5% read on a 30-day basis.